Celltrion has completed the cancellation of 9.11 million treasury shares, equivalent to roughly 4% of s outstanding shares, via an amendment to s articles of incorporation finalized on April 13. The company confirmed on April 14 that this action reduces total shares permanently and represents the largest treasury share cancellation in s history among major Korean pharmaceutical and biotech firms.
Cancellation Details and Shareholder Impact
This move eliminates 74% of Celltrion’s treasury shares, bringing the overall cancellation rate to 3.94%. Valued at approximately 1.778 trillion Korean won based on the previous day’s closing price, the cancellation surpasses the combined value of prior efforts in 2024 (701.3 billion won) and 2025 (895 billion won).
Investors view this as a strong demonstration of shareholder-friendly policies. The reduction directly enhances earnings per share (EPS) by concentrating profs among fewer shares. Key valuation metrics, including price-to-earnings ratio (PER), also improve, signaling potential upside for stock performance.
Link to Executive Compensation
The cancellation incorporates around 3 million shares tied to executive stock options from the STOXX program, aimed at performance-based rewards. Future compensation will shift to new share issuances as needed, pending shareholder approval at the upcoming general meeting.
Strong Financial Performance Underpins Move
Celltrion posted annual sales of 4.1625 trillion won and operating prof of 1.1685 trillion won, achieving a 28.1% margin—a 14.3 percentage point increase year-over-year. Fourth-quarter sales surged 35.8%. Analysts project fiscal sales near 5.3 trillion won and operating prof around 1.8 trillion won.
Remaining treasury shares, about 323 million, posion the company for global mergers, acquisions, or R&D investments to drive strategic growth.
Analyst and Company Perspectives
Among leading analysts, evaluations highlight improving multiples justified by robust fundamentals, though market momentum remains tempered by broader sector dynamics. Operations continue to priorize shareholder value amid competive pressures.
A Celltrion representative stated, “This large-scale cancellation exceeds mere numerical reductions, fulfilling our commment to genuine shareholder benefs.” The executive added, “Such major actions enhance key investment indicators and overall earnings qualy, paving the way for comprehensive business value improvement.”
